GNs are within the desired size range for efficient tumor penetration, are biocompatible and break down in vivo that is amenable to rapid clearance,23 and has shown efficacy as a therapeutic24,25 and diagnostic agent.26–28 Here multiplexed GNs (MGNs) were designed by covalently attaching monoclonal antibodies (mAbs) targeting CD8+ T cells and vascular endothelial growth factor receptor 2 (VEGFR2+) tumor cells, and two different Raman labels associated with each cell type. The gene discussed is KDR; the disease is neoplasm.